ETF Evaluator:
Graniteshares YieldBOOST Biotech ETF ()
Follow This ETF
(as of Aug 26)
Best Performing in Derivative Income Over the Last Year
| 127.0% | YieldMax AMD Option Income Strategy ETF (AMDY) |
| 113.8% | YieldMax MSTR Short Opt Inc Stgy ETF (WNTR) |
| 91.4% | YieldMax Semiconductor Port Opt Inc ETF (CHPY) |
| 90.2% | YieldMax Target 12 Smcndctr Opt Inc ETF (SOXY) |
| 61.8% | YieldMax GOOGL Option Income Stgy ETF (GOOY) |
Risk
Index
Risk
Index
ETF Details
Graniteshares YieldBOOST Biotech ETF Overview
Graniteshares YieldBOOST Biotech ETF (BIOY) is an actively managed Nontraditional Equity Derivative Income exchange-traded fund (ETF). Graniteshares launched the ETF in 2026.
The investment seeks is to achieve 3 times (300%) the income generated from selling options on the S&P Biotechnology Select Industry Index (the “underlying index”) by selling options on leveraged exchange-traded funds designed to deliver 3 times (300%) the daily performance of the underlying index (the “Underlying Leveraged ETF”).
It is an actively managed exchange-traded fund (“ETF”) that seeks to pay weekly distributions by selling put options on the Underlying Leveraged ETF, which provides exposure to 3 times the daily performance of the underlying index. The fund is non-diversified.
About Graniteshares YieldBOOST Biotech ETF (BIOY)
There are 2 members of the management team with an average tenure of 0.24 years: Jeff Klearman (2026) and Ryan Dofflemeyer (2026). Management tenure is more important for actively managed ETFs than passive index ETFs.
Graniteshares YieldBOOST Biotech ETF has 8 securities in its portfolio. The top 10 holdings constitute 55.0% of the ETF’s assets. The ETF meets the SEC requirement of being classified as a nondiversified fund. The ETF is considered to have an ESG focus with its investment selection and management.
Graniteshares YieldBOOST Biotech ETF is part of the Equity global asset class and is within the Nontraditional Equity ETF group. Graniteshares YieldBOOST Biotech ETF has 0.0% of its portfolio invested in foreign issues. The overall assets allocated to domestic stock is -2.6% There is 0.0% allocated to foreign stock, and 0.0% is allocated to preferred stocks. The bond allocation as a percentage of total assets is 0.0% (0.0% domestic bond, 0.0% foreign bond and 0.0% convertible bond). Graniteshares YieldBOOST Biotech ETF has 102.6% of the portfolio in cash.
Assets Under Management
The fund has $837 million in total assets, which is below the $727 million average for the Derivative Income category. Normally, lower assets under management translates to higher average expense ratios, and greater total assets are desired. However, for some investment categories, such as small-cap investing, it may be difficult for the manager to fully employ the desired active strategy if assets grow too large or too quickly.
BIOY Performance and Fees
The expense ratio measures how much of a fund’s assets are used for administrative expenses and operating expenses, including adviser fees and fees for the transfer agent and custodial services. The Graniteshares YieldBOOST Biotech ETF expense ratio is high compared to funds in the Derivative Income category. Graniteshares YieldBOOST Biotech ETF has an expense ratio of 1.07%, which is 29% higher than its category average, making the fund expense ratio grade a D. While it is difficult to predict returns, it is known that high annual expense ratios reduce your rate of return, and excessive fees are difficult to overcome. Active management normally comes with higher expense ratios than passive index management. Certain investment categories such as small company and foreign also normally have higher expense ratios. It is best to compare fund expense ratios against the category averages for meaningful assessments.
High portfolio turnover can translate to higher expenses and lower aftertax returns. Graniteshares YieldBOOST Biotech ETF has a portfolio turnover rate of 0%, which indicates that it holds its assets around /years. By way of comparison, the average portfolio turnover is 69% for the Derivative Income category.
Recently, in the month of July 2026, Graniteshares YieldBOOST Biotech ETF returned -6.2%, which earned it a grade of F, as the Derivative Income category had an average return of -1.5%. The letter grades of A, B, C, D and F are based upon relative rankings within the investment category. A grade of A, for example, would indicate that the return is in the highest 20% for that time period compared to all ETFs in that category.
Graniteshares YieldBOOST Biotech ETF has a trailing yield of 0.00%, which is below the 19.96% category average.
The fund normally distributes its income annually and its capital gains annually.
It’s natural to seek the best-performing investments, but you must consider the relationship between risk and return and the impact of costs and taxes on your realized returns.
For more ETF grades, analysis and screening tools to help your investment discovery, join AAII for a $2, full-access trial. Learn more here: https://invest.aaii.com/membership.
Otherwise, for more information about Graniteshares YieldBOOST Biotech ETF, including its riskiness, submit your email to unlock the rest of the article.
Gain access to exclusive AAII member-only content.
BIOY Trailing NAV Total Returns Data as of 7/31/26
| Last Month |
Last Quarter |
Ann'l. 1Yr |
Ann'l. 3Yr |
Ann'l. 5Yr |
Ann'l. 10Yr |
|
| BIOY Return (NAV) | -6.2% | na | na | na | na | na |
| BIOY Return (Price) | -6.4% | na | na | na | na | na |
| NAV +/- Price Return | 0.154% | na | na | na | na | na |
| Derivative Income Avg | -1.5% | 0.6% | 11.2% | 13.7% | 8.8% | 7.5% |
| BIOY Grade (NAV) | F | na | na | na | na | na |
| +/- Category (NAV) | -4.7% | na | na | na | na | na |
| BIOY Tax-Cost Ratio | na | na | na | na | na | na |
BIOY Annual NAV Total ReturnsData as of 7/31/26
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
| BIOY Return (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| BIOY Return (Price) | na | na | na | na | na | na | na | na | na | na | na |
| NAV +/- Price Ret | na | na | na | na | na | na | na | na | na | na | na |
| Derivative Income Avg | 2.6% | 10.6% | 18.5% | 17.5% | -11.3% | 19.4% | 1.4% | 19.2% | -7.1% | 12.1% | 8.7% |
| BIOY Grade (NAV) | na | na | na | na | na | na | na | na | na | na | na |
| +/- Category | na | na | na | na | na | na | na | na | na | na | na |
| Risk Measures | |
| Beta: | na |
| R-Squared: | na |
| Standard Deviation: | na |
| Category Risk Index: | na |
| Category Risk Rating: | |
| Total Risk Index: | na |
| Total Risk Rating: | |
| Portfolio Characteristics | |
| Yield: | -- |
| Total Assets: | $ 1 Mil |
| Share Class Assets: | $ 1 Mil |
| Turnover: | na |
| Expense Ratio: | 1.07% |
| Index Fund: | No |
| Index Tracked: | N/A |
| Index Weighting: | 100% |
| Leveraged: | No |
| Socially Responsible Fund: | Yes |
| Capital Gains Distribution Frequency: | Annually |
| Income Distribution Frequency: | Annually |
Management Team
| Number of Managers: 2 | |||
| Longest Tenure: 0.2 years | |||
| Average Tenure: 0.2 years | |||
| Managers (Year): Klearman Jeff (2026), Dofflemeyer Ryan (2026) | |||
Portfolio Composition (as of 7/31/26)
| # of Holdings: | 8 |
| % in Top 10 Holdings: | 55.0% |
| Fund is Non-Diversified: | Yes |
| % in Foreign Issues: | 0.0% |
Portfolio Allocation |
|
| Domestic Stock: | -2.6% |
| Foreign Stock: | 0.0% |
| Preferred Stock: | 0.0% |
| Domestic Bond: | 0.0% |
| Foreign Bond: | 0.0% |
| Convertible Bond: | 0.0% |
| Other: | 0.0% |
| Cash: | 102.6% |
Purchase Information
| Legal Structure: | Open Ended Investment Company |
| Fund Family: | Graniteshares |
| Phone Number: | 844-476-8747 |
| Website: | |
| Inception Date: | May 4, 2026 |
Expenses and Fees
| Expense Ratio (%): | 1.07% (Rating: High) |
| Category Average Expense Ratio (%): | 0.83% |
